Collegium Pharmaceutical, Inc.
COLL
$38.58
-$0.19-0.49%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 22.61% | 17.17% | 11.41% | 9.62% | 7.39% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.61% | 17.17% | 11.41% | 9.62% | 7.39% |
| Cost of Revenue | 11.22% | 9.02% | 4.78% | -1.16% | -2.07% |
| Gross Profit | 24.42% | 18.49% | 12.50% | 11.49% | 9.08% |
| SG&A Expenses | 66.00% | 46.50% | 21.42% | 0.56% | -5.35% |
| Depreciation & Amortization | 48.16% | 30.42% | 13.41% | -2.95% | -6.74% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.49% | 32.30% | 14.79% | -1.16% | -5.21% |
| Operating Income | -21.87% | -11.29% | 4.75% | 35.52% | 40.86% |
| Income Before Tax | -62.47% | -49.91% | 30.15% | 502.91% | 2,407.76% |
| Income Tax Expenses | -59.52% | -42.18% | 6.53% | 222.65% | 719.50% |
| Earnings from Continuing Operations | -63.69% | -52.95% | 43.68% | 882.63% | 995.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.69% | -52.95% | 43.68% | 882.63% | 995.02% |
| EBIT | -21.87% | -11.29% | 4.75% | 35.52% | 40.86% |
| EBITDA | 6.47% | 6.31% | 8.52% | 16.97% | 16.85% |
| EPS Basic | -63.00% | -51.97% | 45.89% | 933.96% | 1,019.27% |
| Normalized Basic EPS | -40.32% | -17.50% | 17.69% | 95.29% | 121.82% |
| EPS Diluted | -61.44% | -51.56% | 44.37% | 1,599.65% | 809.00% |
| Normalized Diluted EPS | -38.46% | -15.27% | 12.40% | 74.56% | 87.11% |
| Average Basic Shares Outstanding | -2.19% | -3.33% | -4.36% | -5.10% | -4.23% |
| Average Diluted Shares Outstanding | -7.85% | -8.43% | 0.99% | 6.84% | 13.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |